CEO and Other Selling Stockholders Register Resale of 8.27M Shares, Creating Significant Market Overhang
TPST is trading near its 52-week low of $1.5 (6.0% above the low).
Summary
Tempest Therapeutics filed a final prospectus for the resale of 8.27 million shares by selling stockholders, including CEO Matthew Angel, representing over 57% of outstanding shares, with no proceeds going to the company.
Key Events · Financing and Capital Events · TPST
-
Finalizes Resale Registration
This 424B3 prospectus finalizes the registration for the resale of 8,268,495 shares of common stock by selling stockholders, following the S-3 filings on March 30 and April 2, 2026.
-
Significant Share Overhang
The shares registered for resale constitute approximately 57.65% of the company's currently outstanding common stock, creating a substantial potential supply of shares on the market.
-
CEO Among Selling Stockholders
Matthew Angel, the company's President and CEO, is listed as a selling stockholder, with 4,837,070 shares directly held and additional shares through Factor Bioscience Inc.
-
No Proceeds to Company
Tempest Therapeutics will not receive any proceeds from the sale of these shares, as it is a secondary offering by existing stockholders.
Analysis · TPST · Life Sciences
This 424B3 filing finalizes the registration for the resale of a substantial block of shares by existing stockholders, including CEO Matthew Angel. The 8.27 million shares represent approximately 57.65% of the company's currently outstanding common stock, creating a significant overhang on the stock price. The company will not receive any proceeds from these sales, meaning this event provides no new capital to Tempest Therapeutics, which recently disclosed a "going concern" warning. While the shares were initially issued as consideration for an asset acquisition, the immediate availability for resale by key insiders, particularly the CEO, signals potential selling pressure and raises concerns about insider conviction, especially in light of the company's precarious financial position.
At the time of this filing, TPST was trading at $1.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.7M. The 52-week trading range was $1.50 to $12.23. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.